[1]施宏莹,谢嘉仪,陈小青,等.类风湿关节炎并发肌少症的危险因素分析[J].福建医药杂志,2023,45(02):1-4.
　SHI Hongying,XIE Jiayi,CHEN Xiaoqing,et al.Risk factor analysis of sarcopenia in rheumatoid arthritis[J].FUJIAN MEDICAL JOURNAL,2023,45(02):1-4.
点击复制

类风湿关节炎并发肌少症的危险因素分析()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
45
期数:
2023年02期
页码:
1-4
栏目:
临床研究
出版日期:
2023-04-15

文章信息/Info

Title:
Risk factor analysis of sarcopenia in rheumatoid arthritis
文章编号:
1002-2600(2023)02-0001-04
作者:
施宏莹; 谢嘉仪1; 陈小青2; 颜丽笙; 周明宣
福建医科大学附属第二医院（泉州 362000）
Author(s):
SHI Hongying;  XIE Jiayi;  CHEN Xiaoqing;  YAN Lisheng;  ZHOU Mingxuan
The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, China
关键词:
类风湿关节炎; 肌少症; 肌抑素
Keywords:
rheumatoid arthritis; sarcopenia; myostatin
分类号:
R593.22
文献标志码:
B
摘要:
目的 分析类风湿关节炎（rheumatoid arthritis，RA）并发肌少症的危险因素。方法 收集我院门诊RA患者123例的临床资料、骨密度、体成分、血清肌生成抑制素，将临床资料完整的100例患者分为肌少症组（20例）和无肌少症组（80例）。比较两组的临床特征及肌抑素水平，采用二元逻辑回归分析可能与RA并发肌少症相关的因素。结果 RA患者中肌少症发生率17.89%。与无肌少症组相比，肌少症组RA病程较长（P=0.028），关节肿痛数、ESR、CRP、IL-6、DAS28及HAQ评分、低骨量/骨质疏松发生率、激素使用率显著增高（P=0.000～0.009）。两组脂肪含量指数（FMI）比较，差异无统计学意义（P>0.05）。两组血清肌抑素水平比较，差异无统计学意义（P>0.05）。结论 RA病程长且疾病控制不佳易并发肌少症，IL-6是RA相关肌少症的独立危险因素。
Abstract:
Objective To analyze the risk factors of sarcopenia in patients with rheumatoid arthritis (RA). Methods The clinical data, bone mineral density, body composition and serum myostatin of RA patients in the Second Affiliated Hospital of Fujian Medical University from June 2019 to December 2020 were collected and divided into sarcopenia group and non-sarcopenia group. The clinical characteristics and myostatin levels of the two groups were compared. Binary logistic regression analysis was used to analyze the factors that might be associated with RA complicated with sarcopenia. Results The prevalence of sarcopenia in RA was 17.89%.Compared with the RA with non-sarcopenia group, the duration of RA was longer (P=0.028), swollen joint count, tender joint count, ESR, CRP, IL-6, DAS28 and HAQ scores, the incidence rate of osteoporosis/osteopenia, and the hormone usage rate were significantly higher in the RA with sarcopenia group (P=0.000-0.009). There was no significant difference in fat mass index（FMI) between the two groups (P=0.092). There was no significant difference in serum myostatin level between the two groups (P>0.05). Conclusion The long course of RA and poor disease control may lead to sarcopenia. IL-6 is an independent risk factor for RA-associated sarcopenia.

参考文献/References:

[1] Lin J Z,Liang J J,Ma J D,et al.Myopenia is associated with joint damage in rheumatoid arthritis: a cross-sectional study[J].J Cachexia Sarcopenia Muscle,2019,10(2): 355-367.
[2] Brance M L,Di Gregorio S,Pons-Estel B A,et al.Prevalence of sarcopenia and whole-body composition in rheumatoid arthritis[J].J Clin Rheumatol,2021,27(6): 153-160.
[3] Arnett F C,Edworthy S M,Bloch D A,et al.The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[J].Arthritis Rheum,1988,31(3): 315-324.
[4] Aletaha D,Neogi T,Silman A J,et al.2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative[J].Arthritis Rheum,2010,62(9): 2569-2581.
[5] Fransen J,van Riel P L.The disease activity score and the EULAR response criteria[J].Rheum Dis Clin North Am,2009,35(4): 745-757.
[6] Ward R J,Roberts C C,Bencardino J T,et al.ACR Appropriateness criteria osteoporosis and bone mineral density[J].J Am Coll Radiol,2017,14(5): 189-202.
[7] Chen L K,Woo J,Assantachai P,et al.Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J].J Am Med Dir Assoc,2020,21(3): 300-307.
[8] Cruz-Jentoft A J,Bahat G,Bauer J,et al.Sarcopenia: revised European consensus on definition and diagnosis[J].Age Ageing,2019,48(1): 16-31.
[9] Petermann-Rocha F,Chen M,Gray S R,et al.Factors associated with sarcopenia: a cross-sectional analysis using UK Biobanks[J].Maturitas,2020(133): 60-67.
[10] Müller R,Kull M,Plluste K,et al.Factors associated with low lean mass in early rheumatoid arthritis: a cross-sectional study[J].Medicina (Kaunas),2019,55(11)：730.
[11] Bian A L,Hu H Y,Rong Y D,et al.A study on relationship between elderly sarcopenia and inflammatory factors IL-6 and TNF-α[J].Eur J Med Res,2017,22(1): 25.
[12] Tournadre A,Pereira B,Dutheil F,et al.Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis[J].J Cachexia Sarcopenia Muscle,2017,8(4): 639-646.
[13] Yamada Y,Tada M,Mandai K,et al.Glucocorticoid use is an independent risk factor for developing sarcopenia in patients with rheumatoid arthritis: from the CHIKARA study[J].Clin Rheumatol,2020,39(6): 1757-1764.
[14] Binkley N,Buehring B.Beyond FRAX: its time to consider "sarco-osteopenia"[BF][[BFQ]J].J Clin Densitom,2009,12(4): 413-416.
[15] Mendias C L,Bakhurin K I,Gumucio J P,et al.Haploinsufficiency of myostatin protects against aging-related declines in muscle function and enhances the longevity of mice[J].Aging Cell,2015,14(4): 704-706.
[16] Ju C R,Chen R C.Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease[J].Respir Med,2012,106(1): 102-108.
[17] Becker C,Lord S R,Studenski S A,et al.Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept,randomised,phase 2 trial[J].Lancet Diabetes Endocrinol,2015,3(12): 948-957.

相似文献/References:

[1]许桂平,林帆.肌少症的临床研究进展[J].福建医药杂志,2017,39(4):5.

备注/Memo

备注/Memo:
基金项目：福建省自然科学基金资助项目（2021J01279）；泉州市科技计划项目(2019C071R)
1 赣南医学院第一附属医院；2 通信作者，Email：xiaoqingchen2022@163.com
更新日期/Last Update: 2023-04-15